Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2021 Jun 23;70(11):3337–3348. doi: 10.1007/s00262-021-02986-5

Figure 2. Soluble and cellular biomarkers are significantly altered by mFOLFOX6 and pembrolizumab treatment.

Figure 2.

A heatmap displays soluble immune biomarkers that were assessed on this trial and how they were altered by treatment between baseline (C1D1) and cycle 1 day 15 (C1D15) (A). Significant changes in cellular biomarkers (B) are also displayed. Paired student’s t-test used to compare C1D1 and C1D15 values. *P<0.05. **P<0.01, ***P<0.001, ****P<0.0001.